Keminal SRL
Keminal reported total assets of €2.00m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Keminal shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +1454 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Keminal's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 27 Aug 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 20 May 2022
Keminal's financial analysis
- Solvency-5.6%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Keminal
Keminal's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0505.720.485
- VAT number
- BE0505720485
- Peppol
- Registered · 0208:0505720485 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Nov 2014
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Keminal (SRL) has been based in Ghent since 2014, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 87,089 € and equity of −111,477 €; its revenue is not published. Its solvency stands at -5.6%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Keminal
Companies in the same business, of comparable size and area, outside its group.
- Reprobiol Manufacture of basic pharmaceutical products Ouffet · balance sheet €1.93m
- DR. JAN DE JONGH-Huisarts Manufacture of basic pharmaceutical products Diest · balance sheet €2.13m
- Dr. Naesens en Dr. Kaes Manufacture of basic pharmaceutical products Hasselt · balance sheet €3.39m
- Bioseutica Belgium Manufacture of basic pharmaceutical products Bastogne · balance sheet 836,552 €
- DeuterOncology Manufacture of basic pharmaceutical products Liège · balance sheet 688,028 €
- Diagam Manufacture of basic pharmaceutical products Ath · balance sheet €7.25m
- D2S Pharma Manufacture of basic pharmaceutical products Oudenaarde · balance sheet 582,318 €
- Thymolux Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €6.46m
Frequently asked questions about Keminal
What is the revenue of Keminal?
Keminal files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Keminal?
In Belgium, the VAT number is the company number prefixed with BE: BE0505720485 for Keminal, if the company is VAT-registered. Its company number (CBE) is 0505.720.485.
Where is the registered office of Keminal?
According to the CBE register, the registered office of Keminal is in 9000 Ghent.
What is the equity of Keminal?
At the close of the 2025 financial year, the equity of Keminal amounts to -111,477 €, a solvency of -5.6% of total assets.
Who manages Keminal?
The register lists 1 active mandates at Keminal. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Keminal
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →